NCT06417177 Impact of Early Aging and Menopause on the Vascular Responses to Hypoxia
| NCT ID | NCT06417177 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | University of Missouri-Columbia |
| Condition | Aging |
| Study Type | INTERVENTIONAL |
| Enrollment | 75 participants |
| Start Date | 2024-06-03 |
| Primary Completion | 2026-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 75 participants in total. It began in 2024-06-03 with a primary completion date of 2026-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to examine hypoxic vasodilation and the role of beta-adrenergic receptors in younger premenopausal, perimenopausal, and older postmenopausal women.
Eligibility Criteria
Inclusion Criteria: * Female assigned at birth * Pre, peri- or post-menopausal * Healthy weight (BMI ≥18 and ≤30 kg/m2) Exclusion Criteria: * Male (assigned at birth) * Pregnancy, breastfeeding * Use of hormone replacement therapies * Hysterectomy * Body mass index \>30 kg/m2 * Diagnosed sleep apnea * Current smoking/Nicotine/Drug use * Nerve/neurologic disease * Cardiovascular, hepatic, renal, respiratory disease * Blood pressure ≥140/90 mmHg * Diabetes, Polycystic ovarian syndrome * Communication barriers * Prescription medications * Malignant cancer
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06417177 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 70 Years, studying Aging. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06417177 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06417177 currently recruiting?
Yes, NCT06417177 is actively recruiting participants. Contact the research team at limberglab@missouri.edu for enrollment information.
Where is the NCT06417177 trial being conducted?
This trial is being conducted at Columbia, United States.
Who is sponsoring the NCT06417177 clinical trial?
NCT06417177 is sponsored by University of Missouri-Columbia. The trial plans to enroll 75 participants.